Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3026
Vanda Pharmaceuticals
VNDA
$280M
| $1.68M | ﹤0.01% |
191,036
-31,543
| -14% | -$174K |
2013 Q2
50 quarters
|
|
3027
Symbotic
SYM
$5.62B
| $1.68M | ﹤0.01% |
28,311
+28,280
| +91,226% | +$1.87M |
2022 Q3
13 quarters
|
|
|
AHRT
3028
AH Realty Trust
AHRT
$450M
| $1.68M | ﹤0.01% |
254,277
+40,625
| +19% | +$268K |
2016 Q2
38 quarters
|
|
3029
Perella Weinberg Partners
PWP
$1.22B
| $1.68M | ﹤0.01% |
96,903
+2,183
| +2% | +$40.7K |
2022 Q1
15 quarters
|
|
3030
Crawford & Co Class A
CRD.A
$603M
| $1.67M | ﹤0.01% |
148,795
+6,543
| +5% | +$72.2K |
2019 Q2
26 quarters
|
|
|
AMWD
3031
DELISTED
American Woodmark
AMWD
| $1.67M | ﹤0.01% |
31,045
+5,547
| +22% | +$325K |
2016 Q1
39 quarters
|
|
3032
Kforce
KFRC
$947M
| $1.66M | ﹤0.01% |
53,813
+6,362
| +13% | +$187K |
2016 Q2
38 quarters
|
|
|
PSTL
3033
Postal Realty Trust
PSTL
$686M
| $1.66M | ﹤0.01% |
102,994
+57,354
| +126% | +$882K |
2022 Q1
15 quarters
|
|
|
MBX
3034
MBX Biosciences
MBX
$2.82B
| $1.66M | ﹤0.01% |
52,691
+31,065
| +144% | +$754K |
2024 Q3
5 quarters
|
|
3035
CALL
Otis Worldwide
OTIS
$24.4B
| $1.66M | ﹤0.01% |
19,000
+18,800
| +9,400% | +$1.68M |
2025 Q3
1 quarter
|
|
3036
CALL
IBM
IBM
$210B
| $1.66M | ﹤0.01% |
5,600
-1,400
| -20% | -$419K |
2022 Q4
12 quarters
|
|
|
PDM
3037
Piedmont Realty Trust
PDM
$1.13B
| $1.66M | ﹤0.01% |
198,784
+18,868
| +10% | +$158K |
2013 Q2
50 quarters
|
|
3038
SandRidge Energy
SD
$505M
| $1.65M | ﹤0.01% |
114,618
+8,689
| +8% | +$115K |
2021 Q1
19 quarters
|
|
3039
Aveanna Healthcare
AVAH
$2.75B
| $1.65M | ﹤0.01% |
202,356
+22,997
| +13% | +$208K |
2022 Q1
15 quarters
|
|
3040
Ooma
OOMA
$574M
| $1.65M | ﹤0.01% |
140,647
+14,324
| +11% | +$163K |
2017 Q1
35 quarters
|
|
3041
CALL
Trip.com Group
TCOM
$24B
| $1.65M | ﹤0.01% |
22,900
| – | – |
2025 Q2
2 quarters
|
|
3042
Fox Factory Holding Corp
FOXF
$784M
| $1.64M | ﹤0.01% |
95,975
+10,193
| +12% | +$194K |
2016 Q3
37 quarters
|
|
|
ESPR
3043
DELISTED
Esperion Therapeutics
ESPR
| $1.64M | ﹤0.01% |
443,339
+107,730
| +32% | +$348K |
2013 Q3
49 quarters
|
|
3044
Patria Investments
PAX
$1.65B
| $1.64M | ﹤0.01% |
103,142
+10,415
| +11% | +$156K |
2023 Q2
10 quarters
|
|
|
MAZE
3045
Maze Therapeutics
MAZE
$1.47B
| $1.64M | ﹤0.01% |
39,508
+11,992
| +44% | +$412K |
2025 Q1
3 quarters
|
|
|
SPYM
3046
CALL
State Street SPDR Portfolio S&P 500 ETF
SPYM
$175B
| $1.64M | ﹤0.01% |
+20,400
| New | +$1.62M |
2025 Q4
0 quarters
|
|
|
SPYM
3047
PUT
State Street SPDR Portfolio S&P 500 ETF
SPYM
$175B
| $1.64M | ﹤0.01% |
+20,400
| New | +$1.62M |
2025 Q4
0 quarters
|
|
3048
CALL
Kohl's
KSS
$2.13B
| $1.63M | ﹤0.01% |
80,000
-707,500
| -90% | -$13.3M |
2025 Q3
1 quarter
|
|
|
FIGR
3049
Figure Technology Solutions
FIGR
$6.4B
| $1.63M | ﹤0.01% |
39,976
+22,776
| +132% | +$911K |
2025 Q3
1 quarter
|
|
3050
Yext
YEXT
$644M
| $1.63M | ﹤0.01% |
201,955
+21,390
| +12% | +$180K |
2017 Q2
34 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.